SEARCH · Search PubMed
Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
Insurance systems for controlling costs--quality assurance, preadmission clearance, length-of-stay control--actually add to costs, and also subtract from the quality of patient care. Step one: Eliminate those systems.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
We have evaluated the economic costs to society for the two major types of inflammatory bowel disease, Crohn's disease and ulcerative colitis, using a medical decision algorithm costing methodology augmented by examination of 1988-89 claims data from a major U.S. commercial insurer. The average annual medical cost per patient with Crohn's disease was estimated at $6,561 (1990 U.S. dollars). The total annual medical costs for U.S. Crohn's disease patients in 1990 was estimated at $1.0-1.2 billion. The average annual medical cost per patient with ulcerative colitis was estimated at $1,488. The total annual medical costs for U.S. patients with ulcerative colitis in 1990 was estimated at $0.4-0.6 billion. Adjusting for productivity losses, we estimated the annual economic cost for both diseases at $1.8 billion to $2.6 billion. Analysis of insurance claims data for inflammatory bowel disease patients showed that the distribution of annual medical expenses charged and paid is highly uneven by patient. The top 2% of Crohn's disease patients accounted for 28.9% of total charges and 34.3% of the total amount paid. The top 2% of ulcerative colitis patients accounted for 36.2% of total charges and 39.0% of the total amount paid. We used a multivariate regression model to examine potential cost-effectiveness tradeoffs between different types of medical services in treatment of inflammatory bowel disease.
BACKGROUND: Health care episodes are traditionally created for a specific condition using defined relevant diagnosis and procedure codes and a start and end period. Our goal is to use 1987 to 1989 medical claims data to create distinct episodes of care as a result of injury. METHODS: Claims for 102,000 people younger than 65 years were obtained from Medstat Systems, Inc. Injury claims were identified by International Classification of Diseases, 9th Revision, Clinical Modification diagnosis codes and separated into 10 body regions. Using linked inpatient and outpatient claims data, we established clear zones--a maximum period for a return visit for medical treatment--for each of 10 body regions injured by hospitalization status. These clear zones were used to create episodes of injury. RESULTS: A total of 295,165 injury claims created 79,564 episodes of injury. Limb and trunk injuries typically have the most follow-ups in terms of number of claims and spacing between claims. Brain injuries, even for admitted patients, result in an average of fewer than two follow-up claims. On average, hospitalized patients require only one more follow-up than nonadmitted patients. CONCLUSIONS: This paper presents a method for identifying injury episodes using a medical claims database. The analysis suggests that follow-up to check for minor long-term sequelae of brain injury is rare.
Health care insurance claims were used to track costs associated with hypertension for an employed population. Employees were classified as hypertensive (n = 373), high normal (n = 363), or normotensive (n = 2,411) on the basis of hypertension screening done at the worksite. Claims activity was monitored for the three groups during a three-year period, including periods before, during, and after the screening done at the worksite. The average amount claimed per employee was significantly higher for the hypertensives as compared with the normotensives or high normals, even after adjustment for age, race, sex, salary, marital status, and duration of insurance coverage. There was no significant difference in the average amount claimed per employee between high normals and normotensives. The health care costs for hypertensives are estimated to be about 80% more than those for normotensives. Hospital, physicians, and nursing care accounts for about 50 percentage points of this increment while the remaining 30 percentage points derive from drug costs.
BACKGROUND: Concerns over rising health care costs have led to pressure on health care providers to reduce inpatient costs. METHODS: Inpatient claims data were analyzed for adult users of mental health services (n = 45,579) from a national sample of over 3.8 million privately insured individuals between 1993 and 1995 from the MarketScan database. Costs and annual hospital days per treated patient were compared across diagnostic groups and plan types. RESULTS: Inpatient mental health costs fell 30.5% over the period, driven primarily by decreases in the number of hospital days per treated patient per year (-20.0%), with smaller changes in the proportion of enrollees who received care (-0.2%), and per diem costs (-13.1%). Patients whose primary diagnosis was mild/moderate depression saw the largest decrease in costs per treated patient (44.5%), and those diagnosed with schizophrenia experienced the smallest decrease (23.5%). There was no evidence of substitution of medical for psychiatric care. CONCLUSIONS: Inpatient cost reductions have been substantial and are primarily caused by reductions in the number of inpatient mental health treatment days per treated patient. Further research is needed to evaluate the impact of these changes on outcome, quality of care, and patient satisfaction.
Explore the source record for details and available documents.
An analysis of medical liability claims for lipoplasty (liposuction) from January of 1985 through June of 1998 compared the insurance industry experience of plastic surgeons with that of other physicians. The Data Sharing Project database of the Physician Insurers Association of America, a trade association of professional liability companies owned and operated by medical professionals that collectively insure approximately 60 percent of America's private practice physicians, was queried. Of the nearly 45,000 total entries in the database, 292 were claims for adverse events related to lipoplasty or liposuction. These raw data were stratified by physician specialty, severity of complication, practice location, patient gender, indemnity payment, and other insurance industry-relevant variables. To simplify interspecialty comparisons, we normalized the claims rate to incidents per 100 insured physicians. The indexed lipoplasty claims rate was 3.0 per 100 insured plastic surgeons and 4.1 for other surgeons; the indexed lipoplasty claims rate for nonsurgical specialists was 2.5 per 100 insured dermatologists and 2.3 for other nonsurgeons. The higher claims rate for surgeons most likely reflects the wider scope of full-service aesthetic surgery performed by surgical specialists. Nearly two-thirds of claims (65.4 percent) during the 13-year survey period were the result of hospital-based lipoplasty; 20.9 percent were office-based claims. The prevalence of hospital-based claims may be a consequence of both historical bias introduced by hospital-based specialty surgery in the early years and prudent patient safety considerations during performance of complex or prolonged procedures in more recent years.Two-thirds of the claims (67 percent) arose from informed-consent or breach-of-contract issues, far higher than the 26 percent aggregate claims norm. The mean indemnity payment was $94,534 per lipoplasty claim; claims paid against board-certified specialists averaged $83,350. Consistent with national lipoplasty demographics, 87 percent of claims were brought by women and 13 percent were brought by men. Seven fatalities (three women and four men) were noted; cause of death is not recorded in this type of database.
STUDY DESIGN: A retrospective analysis of back pain claim data from two sources, a workers' compensation provider and Washington State Department of Labor and Industries. The Workers' Compensation Provider claim data were examined over a 9-year period, 1987-1995, and the Washington claim data were examined over a 5-year period, 1991-1995. In addition, a third source of data, reports of back pain from the the Bureau of Labor Statistics, was examined over a 4-year period, 1992-1995. OBJECTIVES: To characterize occupational low back pain trends in the United States. More specifically, trends in back pain rates and costs as well as back injury rates from the Bureau of Labor Statistics were discerned. SUMMARY OF BACKGROUND DATA: The literature often refers to a recent rise in occupational low back pain. However, the question is: Do empirical data support this notion? METHODS: Retrospective analysis of workers' compensation provider, Washington State, and Bureau of Labor Statistics data. RESULTS: The U.S. estimate of the annual low back pain claim rate decreased 34% between 1987 and 1995, although the trend was not monotonic. There was a sharper decrease in the U.S. estimate of the annual low back pain claim costs during this time (58%). In 1995, however, occupational low back pain remained a major problem in the U.S.: an estimated $8.8 billion was spent on low back pain claims, and the rate of filing low back pain claims was 1.8 per 100 workers. CONCLUSIONS: Evidence of a rise in occupational low back pain was not discerned for the 8-year period studied. Data from three sources support this finding. However, occupational back pain remains a major problem in the U.S.
OBJECTIVE: To estimate the rate of therapy continuation among women using six different hormone replacement therapies (HRTs). DESIGN: A retrospective, longitudinal analysis of pharmacy claims data was conducted for 7,120 women who were new users of six HRT regimens. Continuation rates of therapies were examined at the end of the 9-month period. In addition, the odds ratio of continuation for each product was determined using a logistic model, which controlled for the potential influence of a patient's age and a provider's age, gender, specialty, and geographical location. RESULTS: Treatment continuation rates at the end of the 9-month period were significantly higher among patients prescribed oral 1 mg norethindrone acetate/5 microgram ethinyl estradiol (EE) (femhrt, Pfizer Inc, New York, NY, USA) compared with other HRT regimens. Patients prescribed 1 mg norethindrone acetate/5 microgram EE were 52% more likely to continue therapy compared with patients prescribed 0.625 mg conjugated equine estrogens/2.5 mg or 5 mg medroxyprogesterone acetate (Prempro, Wyeth, Madison, NJ, USA). Significantly higher rates of therapy continuation were seen in women aged 55 years or older, those who did not switch HRT during the analysis, those who received care in the central and northeast regions of the United States, and those who were seen by obstetricians/gynecologists (v primary care physicians) or female (v male) providers. CONCLUSIONS: The higher rates of treatment continuation seen with newer continuous combined HRTs, such as 1 mg norethindrone acetate/5 microgram EE, may lead to improved long-term compliance and, therefore, better protection against osteoporosis in postmenopausal women.
STUDY DESIGN: Cross-sectional analysis of analgesic use by patients with low back pain (LBP). OBJECTIVES: To describe patterns of analgesic use and their cost implications for the use of other care services among individuals with LBP enrolled in a health insurance plan during 2001. It was hypothesized that the use of analgesics would be most frequent among patients with LBP with neurologic findings. SUMMARY OF BACKGROUND DATA: National guidelines have recommended analgesics as the primary pharmacologic treatment of LBP. The choice of specific analgesics has major cost and service use implications. METHODS: The University of Pittsburgh Health System includes 18 affiliated hospitals, more than 5000 physicians, and a commercial health plan with 255,958 members in 2001. This study uses the System Health Plan's insurance claims database to identify members who had services provided for one of 66 International Classification of Diseases, Version 9, Clinical Modification codes that identify mechanical LBP (n = 17,148). RESULTS: In 2001, 7631 (43.5%) members with claims for LBP services had no analgesic pharmacy claims. The other 9517 (55.5%) had analgesics claims costing a total of $1.4 million; 68% of claimants were prescribed an opioid and 58% nonselective nonsteroidal antiinflammatory drugs (NSAID). The costs of opioids, NSAID, and cyclooxygenase-2 selective NSAID for patients with LBP represented 48%, 24%, and 28%, respectively, of total health plan expenditures for all uses of these drugs, including cancer. Opioid use was associated with the high volume usage of LBP care services. Patients with LBP with and without neurologic involvement and those with acquired lumbar spine structural disorders had similar patterns of analgesic use: those with congenital structural disorders were less likely to use analgesics; and those with psychogenic pain and LBP related to orthopedic devices were more likely to use opioids. CONCLUSIONS: With this health plan, a high proportion of patients with LBP had claims for opioids during 2001. The use of opioids by patients with LBP represents a major cost for the health plan, and is associated with specific patient characteristics and their use of other LBP services.
This study examines how wellness scores generated from the Health Risk Appraisal are associated with prospective medical claims costs, controlling for age, gender, and disease status. The study was conducted among 19,861 active employees who participated in the Health Risk Appraisal and selected indemnity or PPO medical plans from 1996 to 1998. A multiple regression model based on group averages of age, gender, disease status, and wellness score levels was developed among a randomly selected screening subsample (n=10,172) from the study sample. Total medical claim costs of -$56, $88, and $3574 were estimated for one additional point on the wellness score, 1 year of additional age, and an existing major disease, respectively. No significant differences were found between the model predicted and actual medical claims costs for the individuals in both screening and calibration (n=9689) subsamples.
Significant attention has been paid to the cost of treating patients with anti-TNF agents for diseases including Crohn's disease (CD). To evaluate the actual expenditures for infliximab in routine clinical practice, the authors examined patterns of administration and reimbursement among commercially-insured patients receiving infliximab for CD. Integrated pharmacy and medical claims data were obtained from 78 US health plans. Data from CD patients treated with infliximab between June 2000 and December 2003 were analyzed. Each claim for an infusion (HCPCS code J1745) represented a single observation. Descriptive statistics were generated for the number of vials billed for each infusion, total charged amount (ie, the amount submitted by providers), and total paid amount (ie, the amount reimbursed by the health plan, net of any patient copayment, coinsurance, or deductible). A total of 2230 CD patients were identified; of the original total of 9724 infusions, 168 were not evaluable because of data quality issues, yielding cost evaluation for 9556 total infusions. At each infusion, claims for a mean (SD) of 4.79 (1.74) vials were submitted (median = 5). Corresponding charged amounts were 4441 dollars (1778 dollars) (median = 4099 dollars); paid amounts averaged 2793 dollars (990 dollars) (median = 2628 dollars). Charged and paid amounts per vial billed averaged 927 dollars and 583 dollars, respectively. The average cost of administering a dose of infliximab to a commercial insurer is approximately 2800 dollars. Assumptions regarding infusion costs for infliximab based on charged amounts may be misleading; the true costs of administering infliximab in routine practice are likely to be lower than that reported for charged amounts.
BACKGROUND: Researchers need valid methods to assess whether patients are taking their antidepressant medications. Two important sources of data on drug exposure are patients' self-reports and pharmacy claims. OBJECTIVE: To compare self-report and claims data for antidepressant exposure. RESEARCH DESIGN: Cross-sectional analysis. SUBJECTS: This study comprised 422 contemporaneous self-report and claims data points obtained from 164 unique patients in a longitudinal depression study in which patients completed up to five surveys during an 18-month period. MEASURES: For the self-report measure, the following question was asked: Do you now take any prescription medicines for depression? Using claims data, patients were considered to be using an antidepressant if they had filled at least one antidepressant prescription in the 90 days before survey dates. RESULTS: Self-report and claims agreed in 85% (358/422) of cases, with a kappa of 0.69. Eighty-eight percent (56/64) of discrepant cases using other study data sources was resolved. Reasons for discrepancies included the use of medications for conditions other than depression (32/64), recent AD discontinuations (6/64), samples usage (3/64), and low-frequency/PRN use (7/64). CONCLUSIONS: Self-report and claims showed good concordance, but they reflect different truths. Self-report identifies medications intended primarily for the treatment of depressive disorders, whereas claims data identify use of medicines with antidepressant effects. Our assessment of discordant cases showed self-report to be more valid than claims to assess current antidepressant use for depression therapy.